cytochrome P450 family 4 subfamily F member 29, pseudogeneGenealiases: 4F-se4[6:7:8] · C21orf15 · CYP4F-se4[6:7:8] · CYP4F3LP
Q-omics provides the consensus-scored CYP4F29P profile across patient tissues and cancer cell-line models. CYP4F29P expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CYP4F29P is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, CYP4F29P RNA expression shows 14,670 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, and UVM as cancer lineages where CYP4F29P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP4F29P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP4F29P survival associations across molecular data types. CYP4F29P RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP4F29P RNA expression–survival associations across cancer types. High CYP4F29P expression shows unfavorable associations in KIRC and ACC, but favorable associations in HNSC, BLCA, MESO and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CYP4F29P RNA expression.
This table summarizes CYP4F29P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CYP4F29P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP4F29P shows lower tumor expression in HNSC, KICH, LUAD, COAD, LUSC and BRCA. The HNSC box plot shows higher CYP4F29P RNA expression in normal versus tumor tissue (log2 FC = −2.794, t-test p < 0.001).
This table shows molecular features associated with CYP4F29P in patient tissues and cancer cell lines. In patient samples, CYP4F29P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
